More MS news articles for Nov 2001

Three New Clinical Studies Released at the Female Sexual Function Forum Provide Further Proof of UroMetrics' Eros Therapy(TM) Device's Effectiveness

http://news.excite.com/news/pr/011114/mn-urometrics-studies

Wed, Nov 14 7:12 PM EST

ST. PAUL, Minn., Nov. 14 /PRNewswire/ -- UroMetrics, Inc. today announced the results of three new company-sponsored clinical study results presented at the annual Female Sexual Function Forum (FSFF) in Boston, Mass., the weekend of October 26, 2001.

The FSFF officially changed its name to the International Society for the Study of Women's Sexual Health as of Monday, October 29, 2001. It is an international multi-disciplinary, academic and scientific organization whose purposes are to provide opportunities for communication among scholars, researchers and practitioners about female sexual function and women's sexual experience; to support the highest standards of ethics and professionalism in research, education and clinical practice of female sexuality; and provide the public with accurate information about female sexuality and female sexual health.

Female Sexual Dysfunction (FSD) is a medical condition that affects more than 43 percent of American women, according to the Journal of the American Medical Association. FSD can have physical and/or psychological causes. Physical causes of FSD include inadequate blood flow to the clitoris and genitalia, age, menopause, diabetes, heart disease, high blood pressure, high cholesterol, pelvic surgery, radiation therapy, trauma, side effects from medication, and smoking.

The Eros Therapy(TM) device was cleared to market by the Food and Drug Administration (FDA) in April 2000, and remains the only clinically proven product on the market for women with FSD, specifically arousal and orgasmic disorders. It is a non-invasive conditioning therapy designed to increase blood flow to the clitoris and genital area to restore a woman's sexual function and ability to enjoy sex again. The Eros Therapy is a small hand-held device that the patient uses in the privacy of her home. Pat of Minneapolis, Minn., a patient in the initial study, said, "At first I did not immediately see results but after using the Eros Therapy device for several weeks, I started to feel like my sex life was back where it used to be and life was good again."

A follow-up clinical study completed in October 2000 and published in the May 2001 edition of the Journal of Gender Specific Medicine, further documented the effectiveness of the Eros Therapy device in increasing lubrication, sensation, orgasm and sexual satisfaction. Results of three new research studies support the findings of the initial clinical studies and demonstrate the effectiveness of the Eros Therapy device for patients with FSD and certain medical conditions.

The New Studies:

A Non-Pharmacological Method to Increase Vaginal Blood Flow in Patients with Sexual Arousal Disorder Authors: Rachel N. Pauls, M.D., Laura Berman, Ph.D., and Jennifer Berman, M.D., Los Angeles, Calif.

The purpose of this study was to determine the effects of the Eros Therapy device on vaginal blood flow in patients with sexual arousal disorder. Twelve study participants ranged in age from 25-68 and had their vaginal blood flow measured using a Duplex Doppler ultrasound test. Seven participants were pre-menopausal and five were post-menopausal. The results confirmed that the Eros Therapy device causes a significant increase in vaginal blood flow in pre and post-menopausal women with sexual arousal disorder.

These findings support previous data demonstrating that the use of the Eros Therapy device increases vaginal lubrication and sexual arousal. "Lack of lubrication is one of the most frequent complaints made by women experiencing sexual dissatisfaction," said Dr. Jennifer Berman, M.D. and co-author of the study. "This study demonstrates that the Eros Therapy device increases vaginal blood flow. This evidence indicates that the Eros Therapy device increases lubrication and may be a natural, safe and effective way to enhance lubrication." Sister and co-author of the study, Laura Berman, Ph.D., agrees adding, "Lubrication is a central part of sexual arousal and pleasure."

A Prospective Duplex Doppler Ultrasonographic Study in Women with Sexual Arousal Disorder to Objectively assess Genital Engorgement following Therapeutic Use with The Eros Therapy Device Authors: Elizabeth Flaherty, Scott Maitland, Sandra P. Garcia, Ricardo Munarriz, Lily Talakoub and Irwin Goldstein; Center for Sexual Medicine, Department of Urology, Boston University School of Medicine

The purpose of this study was to obtain objective information regarding the effectiveness of the Eros Therapy device to increase blood flow to the clitoris following Eros Therapy device use in women with sexual arousal disorder. Duplex Doppler ultrasound was used to examine seven women, ages ranging from 25 to 63 years old, before and after the use of the Eros Therapy device. Results showed a 33 percent increase in clitoral and corpus spongiosum diameter, a 350 percent increase in clitoral peak systolic velocity values and a 400 percent increase in end-diastolic velocity values.

"The good news is that this new study documents what we already knew," said Dr. Irwin Goldstein, Center for Sexual Medicine and Department of Urology at Boston University School of Medicine. "The benefits of the Eros Therapy device are directly attributed to increasing blood flow to the clitoris and genitalia. The Eros Therapy device is a first-line treatment for women with arousal and orgasmic disorders because there are no side effects or drug interactions, and the benefits of improved blood flow can improve sexual function."

Efficacy of The Eros Therapy for Sexual Dysfunction in Women with Cervical Cancer Treated with Radiation Therapy: Preliminary Results Authors: Maryann Schroder, Ph.D., Steven Waggoner, M.D., Jacob Rotmensch, M.D., S. Diane Yamada, M.D., and Arno J. Mundt, M.D., Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.

The purpose of this study was to evaluate the effectiveness of the Eros Therapy device for treatment of sexual dysfunction in women with a history of cervical cancer treated with radiation therapy. Each year, cervical cancer is diagnosed in 500,000 women, worldwide. Sexual dysfunction is common among this group due to marked physical changes of the pelvic organs. Eleven patients were evaluated and all reported symptoms of severe sexual dysfunction. After three months of using the Eros Therapy four times weekly, patients reported significant improvements in desire, arousal, lubrication, orgasm and satisfaction.

"After the cervical cancer treatment, I felt abnormal, sex was a chore, I felt like just a receptacle for sex, and got no pleasure," said a 44-year-old study participant based in Chicago, Ill. "The Eros gave me my life back. Now everything in my body feels free and released and I even sleep with the Eros Therapy under my pillow. Sex is truly a joint venture with my partner and I feel sexy, and good about myself again. My husband and I feel 20 years younger. It's the best sex ever." Another study participant was so pleased with the Eros Therapy device results, she even invited the researchers to her wedding.

"Our results suggest that the Eros Therapy represents the first successful treatment of sexual dysfunction in these women," said Maryann Schroder, Ph.D. and co-author of the study. "Sexual desire, arousal, lubrication, orgasm and satisfaction increased significantly. If the Eros Therapy can work on irradiated tissue, just imagine the possibilities for other patients with vascular insufficiency."

All three of these new Eros Therapy device FSD studies further document the direct correlation between increasing blood flow to the clitoris and genitalia, and the significant increases in lubrication, sensation, ability to achieve an orgasm, and overall sexual satisfaction that were the reported results in the initial clinical trials. Additional UroMetrics-sponsored clinical studies are in process for release in 2002 demonstrating the effectiveness of the Eros Therapy device in treating women with FSD related to menopause, diabetes and multiple sclerosis.

UroMetrics is a privately held medical device company based in St. Paul, Minn. For more information on the Eros Therapy device or UroMetrics, call 651-774-1552, or visit online at http://www.eros-therapy.com and http://www.urometrics.com

 
©2001 At Home Corporation.